LAMにおけるシロリムスの有効性と安全性

基本情報

NCT ID

NCT00414648

ステータス

完了

試験のフェーズ

第3相

試験タイプ

介入

目標被験者数

89

治験依頼者名

University of Cincinnati

概要

Lymphangioleiomyomatosis (LAM) is a rare lung disease of women that is caused by genetic mutations. It results in the uncontrolled growth of an unusual type of smooth muscle cell in the lung. These cells invade lung tissue, including the airways, blood vessels, and lymph vessels, and restrict the flow of air, blood, and lymph, respectively. Respiratory failure, lung collapse (pneumothorax), and pleural effusions (chylothorax) are hallmarks of the disease. This study will evaluate the safety and effectiveness of sirolimus, an inhibitor of the mTOR pathway, in stabilizing or improving lung function in people with LAM.

対象疾患

介入

依頼者（Sponsor）

実施施設 (2)